Authors
Latest:
Engaging Physicians, Staff and Patients for Oncology TrialsAccruing patients depends greatly on engaged, enthusiastic PIs, as they are the gatekeepers in helping patients decide to participate in clinical trials. Building staff awareness and enthusiasm are also essential for retaining participants.
Latest:
How Will Technology Drive Global Clinical Trial Change by 2025?Exploring three pivotal technology areas that could reshape global studies over the next 10 years.
Latest:
Investigator Characteristics & Patient Recruitment in ALLHATAnalysis of the largest antihypertensive trial ever offers useful blueprint for sites in boosting subject enrollment.
Latest:
Investigator Characteristics & Patient Recruitment in ALLHATAnalysis of the largest antihypertensive trial ever offers useful blueprint for sites in boosting subject enrollment.
Latest:
Exploring the Role of the Regional CoordinatorHow one large academic trial adopted a coordinating center model-helping drive early-model RBM gains
Latest:
Investigator Characteristics & Patient Recruitment in ALLHATAnalysis of the largest antihypertensive trial ever offers useful blueprint for sites in boosting subject enrollment.
Latest:
Exploring the Role of the Regional CoordinatorHow one large academic trial adopted a coordinating center model-helping drive early-model RBM gains
Latest:
Investigator Characteristics & Patient Recruitment in ALLHATAnalysis of the largest antihypertensive trial ever offers useful blueprint for sites in boosting subject enrollment.
Latest:
Exploring the Role of the Regional CoordinatorHow one large academic trial adopted a coordinating center model-helping drive early-model RBM gains
Latest:
Investigator Characteristics & Patient Recruitment in ALLHATAnalysis of the largest antihypertensive trial ever offers useful blueprint for sites in boosting subject enrollment.
Latest:
How Cold Chain Logistics Work in Clinical TrialsWithout question, advanced cellular and gene therapies require well-defined cold-chain management solutions that reduce risk and include all elements of packaging, data collection and logistics expertise to ensure high-quality, effective treatments reach the point of care, and ultimately, the patient.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Safety 360 – A Holistic Approach to PharmacovigilanceThe industry is experiencing a paradigm shift from pharmacovigilance rooted in case processing and compliance reporting to a safety program built around benefit-risk management.
Latest:
Overcoming Early Phase Oncology ChallengesHow to meet the rigorous safety and efficacy demands critical to evaluating newer targeted cancer therapies.
Latest:
Critical Appraisal of Clinical Quality Assurance Based on Benchmarking Results: Past - Present - FutureA follow-up survey on clinical quality assurance (CQA) assesses current industry best practices compared to a decade ago, and provides recommendations on this key component of quality management for the future.
Latest:
Critical Appraisal of Clinical Quality Assurance Based on Benchmarking Results: Past - Present - FutureA follow-up survey on clinical quality assurance (CQA) assesses current industry best practices compared to a decade ago, and provides recommendations on this key component of quality management for the future.
Latest:
Critical Appraisal of Clinical Quality Assurance Based on Benchmarking Results: Past - Present - FutureA follow-up survey on clinical quality assurance (CQA) assesses current industry best practices compared to a decade ago, and provides recommendations on this key component of quality management for the future.
Latest:
An IRB’s Perspective on ePROThe information in this article serves as a good start by providing factors to keep in mind if your organization is considering adopting ePRO. Appropriateness of ePRO often varies by study and is evaluated individually. As the research landscape continues to shift, being prepared will help ensure a successful IRB review of your study and facilitate a smoother research process overall.
Latest:
An IRB’s Perspective on ePROThe information in this article serves as a good start by providing factors to keep in mind if your organization is considering adopting ePRO. Appropriateness of ePRO often varies by study and is evaluated individually. As the research landscape continues to shift, being prepared will help ensure a successful IRB review of your study and facilitate a smoother research process overall.
Latest:
6 Ways to Protect the Blind in Clinical TrialsAn overview of clinical supply blinding methods in the context of the current research environment.
Latest:
6 Ways to Protect the Blind in Clinical TrialsAn overview of clinical supply blinding methods in the context of the current research environment.
Latest:
6 Ways to Protect the Blind in Clinical TrialsAn overview of clinical supply blinding methods in the context of the current research environment.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
Latest:
Right Time, Right ChannelIndustry news focusing on the people and organizations who work in the clinical trials profession.
Latest:
Streamline and Improve Study Start-UpWork is needed if true efficiencies are to be gained in clinical trial performance.
Latest:
Evaluation of Data for Multi-Regional Trials: A Three-Layer ApproachPlanning for ethnic sensitivity from a scientific and regulatory perspective.
